Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Force GOLD: Valbenazine in pediatric Tourette Syndrome
NCT03325010Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of valbenazine in Tourette syndrome (TS), sponsored by Neurocrine Biosciences. Started Oct 2017; status: completed.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03325010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325010.